Bayer AGXSWX:BAYN -5.87%35 EV-to-EBITDA is 27.02 as of Jul. 09, 2026, which is 373% above its 10-year median of 5.71. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.67 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 739 Drug Manufacturers companies, Bayer AG ranks worse than 77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bayer AG's enterprise value is CHF71,405 Mil.
Bayer AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF2,643 Mil. Therefore, Bayer AG's EV-to-EBITDA for today is 27.02.
The historical rank and industry rank for Bayer AG's EV-to-EBITDA or its related term are showing as below:
XSWX:BAYN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.87 Med: 5.71 Max: 43.31
Current: 26.3
During the past 13 years, the highest EV-to-EBITDA of Bayer AG was 43.31. The lowest was -51.87. And the median was 5.71.
XSWX:BAYN's EV-to-EBITDA is ranked worse than 77% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs XSWX:BAYN: 26.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Bayer AG (XSWX:BAYN) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bayer AG's share price for today is CHF45.72.
Bayer AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-2.111.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bayer AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BAYN vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Bayer AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bayer AG's EV-to-EBITDA falls into.
Bayer AG's current Enterprise Value is CHF71,405 Mil.
Bayer AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,643 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bayer AG (XSWX:BAYN) has a EV-to-EBITDA of 27.02 as of Jul. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bayer AG. This is 373% above median its historical median of 5.71. According to the industry distribution chart, Bayer AG ranks #569 out of 739 companies in the Drug Manufacturers industry, placing it in the top 77%.
Is Bayer AG's EV-to-EBITDA too high?
Bayer AG's current EV-to-EBITDA of 27.02 is 373% above median its 10-year median of 5.71. The Drug Manufacturers industry median EV-to-EBITDA is 12.78. Bayer AG's value of 27.02 is 111.4% above this industry median. Based on the distribution chart, Bayer AG ranks #569 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #569 out of 739 companies for EV-to-EBITDA. This places Bayer AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.78. Bayer AG's value of 27.02 is 111.4% above this benchmark. While the company's 10-year median is 5.71 vs. the industry median of 12.78, Bayer AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.78, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current EV-to-EBITDA of 27.02 is 111.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bayer AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current EV-to-EBITDA is 27.02, which is 373% above median its own 10-year median of 5.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.67, compared to a current price of CHF45.72 — trading 85.3% above its estimated fair value. The current EV-to-EBITDA is 27.02, which is 373% above median its 10-year median of 5.71 and 111.4% above the Drug Manufacturers industry median of 12.78. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current EV-to-EBITDA is 27.02 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (XSWX:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of CHF45.72 is trading 85.3% above its estimated GF Value™ of CHF24.67.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for XSWX:BAYN:
EV-to-EBITDA: 27.02 (373% above median its 10-year median of 5.71)
GF Value™: CHF24.67 vs. price of CHF45.72 (85.3% above fair value)
Industry Position: 111.4% above the Drug Manufacturers median (#569 of 739)
No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score
Get the complete analysis for XSWX:BAYN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BAYN has been successfully added to your 
